Human choriogonadotropiri (hCG) and free hCG-/3 values for 934 serum samples from patients with seminomatous or nonseminomatous testicular cancer were measured by highly specific immunoradiometric assays (IRMA5). in nonseminoma samples, hCG and hCG-/3 were highly correlated (r = 0.82, P <0.001). Of 112 "marker-positive" seminoma samples, only 46 (41.1%) showed both increased hCG and hCG-/3. In 39 cases (34.8%) only hCG-/3 and in 27 cases (24.1%) only dimer-hCG was increased. This makes the determination of hCG and hCG-/3, either by two assays or by a single hCG (+hCG-p) assay, most reliable in these patients. For all samples, hCG (+hCG-f3) was measured by a polyclonal RIA and a monoclonal IRMA, which differed in their cross-reactivities with hCG
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hCG, human choriogonadotropin; IRMA, immunoradiometric assay; mAb, monoclonal antibody; and 1.IRP, First International Reference Preparation. Received June 5, 1989 ; accepted October 24, 1989. specificity and sensitivity in serum samples from these patients. To elucidate this question, we determined hCG in a large number of serum samples from patients with seminomatous and nonseminomatous testicular cancer by comparably applying the following assay methods: an immunoradiometric assay (IRMA) for specific determination of dimer-hCG with negligible cross-reactivity with the free /3-subunit, an IRMA for specific determination of the free /3-subunit, and two assays-a conventional double-antibody radioimmunoassay (RIA) and a monoclonal IRMAthat measure both hCG and its free /3-subunit.
Our results confirm the presence of the free /3-subunit of hCG in most patients with testicular cancer. In some samples from patients with pure seminoma, /3-subunit concentrations were increased but no dimer-hCG was detectable. On the basis of these data, we provide evidence that hCG (+hCG-/3) assays are the most reliable for use in diagnosis and follow-up of testicular cancer patients.
Subjects and Methods

Serum Samples
This study included 934 serum samples from 325 consecutive patients with testicular cancer who were referred to our laboratory for routine determination of hCG. Primary tumors had been classified according to the W.H.O. staging procedures, and therapy was conducted according to the manual of Tumorzentrum Munich (12). Of these samples, 279 were from 125 patients with pure seminoma and 655 samples from 200 patients with nonseminomathus testicular cancer. One hundred thirty-two serum samples had been taken at the patients' first presentation before initiation of treatment and the other 802 samples had been taken during the patients' follow-up. Serum samples from 52 healthy men (ages 17-40 years) served as controls.
Immunoassays for Determination of Dimer-hCG, Free hCG-/3-Subunit, and hCG (+hCG-/3)
Monoclonal antibodies (mAbs), produced from immunization with dimer-hCG (mAb 11/6, 3/6, 12/17) and from immunization with the free /3-subunit of hCG (mAb 2/6), were produced as ascites fluid in Balb c mice, as recently described (13). Specific, two-site IRMA5 were developed for determination of dimer-hCG (mAb 3/6-11/6), the free /3-subunit (mAb 2/6-12/17), and hCG (+hCG-/3) (mAb 3/6 -12/17) as recently described (14).
MAbs were prepared for use by the following procedures: The first antibody (mAb 2/6 or 3/6) was used as a 1000-fold dilution of ascites fluid in ammonium bicarbonate buffer (50 mmolJL, pH 8.0) for coating polystyrene tubes (Startubes; Nunc, Wiesbaden, F.R.G.), 0.5 mL per tube being incubated at 4#{176}C for 24 h. The second antibody (mAb 11/6 or 12/17) was purified before labeling by application to a 1. method. Coated tubes were saturated with a 50 mL/L solution of calf serum and, after decanting, 0.1 mL of standard or serum samples was added. After 2 h at room temperature, the tubes were washed twice with 1 mL of Tris buffer (10 mmollL, pH 8.0), containing 0.05 g of Tween 20 per liter (washing buffer). We then added 0.2 mL of the labeled second antibody and incubated the samples at room temperature for 2 h. After the end of incubation, the tubes were washed three times with washing buffer and the radioactivity was counted.
We additionally determined hCG (+hCG-/3) by a doubleantibody RIA with use of polyclonal rabbit anti-hCG-/3 antibody as previously described (15) .
The hCG (+hCG-/3) RIA and the IRMASfor determination of dimer-hCG and hCG (+hCG-/3) were standardized against the First International Reference Preparation (IRP) 75/537, supplied from the National Institute for Biological Standards (London, U.K.). The IRMAfor determination of the /3-subunit was calibrated to the 1.IRP 75/551 for hCG-13.
Commercial Kits for Determining hCG
Eleven commercial kits for determination of hCG were investigated for their cross-reactivity with the free /3-subunit. Five kits were double-antibody RIAs based on use of a polyclonal rabbit anti-hCG-/3 antibody. One RIA kit involved use of a monoclonal anti-hCG antibody. Four kits were mrLs with monoclonal antibodies against hCG, and one kit was an enzyme-linked immunosorbent assay with one polyclonal and one monoclonal anti-hCG antibody.
The following kits were included in the study: "Amerlex-M /3-hCG RIA" (Amersham All assays were performed according to the instructions of the kit manufacturers and standardized against the 1.IRP 75/537.
Statistical analysis involved calculation of the coefficient of correlation and use of the Mann-Whitney U-test.
Results
Analytical Performance Table 1 shows the detection limits of the hCG-IRMA, the hCG-/3 IRMA, the hCG (+hCG-/3) IRMA, and the hCG (+hCG-/3) RIA, and gives their cross-reactivities with other glycoprotein hormones. The cross-reactivity with the free /3-subunit of hCG, evaluated on a molar basis, was <0.1% for the hCG-IRMA (3/6-11/6), 720% for the hCG (+hCG-/3) IRMA (3/6-12/17), and 234% for the polyclonal hCG (+hCG-/3) RIA. The reference (normal) ranges of these assays, based on the results of serum samples from 52 healthy men, were <5 mt. unitsfL for the dimer-hCG IRMA, the hCG (+hCG-/3) IRMA, and the hCG (+hCG-/3) RIA, and 0.2 mt. unitlL for the hCG-/3 IRMA.
Precision studies revealed within-run coefficients of variation (CVs) between 5.6% and 9.8% for control samples 
Dimer-hCG and the Free hCG-f3-Subunit in Testicular Cancer Patients
Of the 934 serum samples, 491 showed increases of dimer-hCG or the free /3-subunit and were selected for further investigations; 379 of these samples were from patients with nonseminomathus testicular cancer and 112 were from seminoma patients.
Fifty-five of the nonseminoma samples and 51 of the seminoma samples were taken at the patients' first presentation, before the initiation of treatment. Figure 1 shows the hCG and hCG-/3 values in these patients. In patients with nonseminomatous testicular cancer, dimer-hCG concentrations ranged from 13 to 2 927 210 mt. units/L (median 6993 mt. unitsIL) and hCG-/3 from 0.05 to 5170 mt. units/L (median 13 mt. umtslL). In seminoma patients, both hCG and hCG-/3 were significantly lower (hCG, range 1.0-2381 mt. unitsfL; median 10 mt. units/L; P <0.001; hCG-fl, range 0.05-37; median 0.5 mt. unit/L; P <0.001).
An isolated increase of dimer-hCG without detectable free hCG-/3 was observed in 2 of 55 (3.6%) nonseminoma and in 10 of 51 (19.6%) "marker-positive" seminoma patients. Increased concentrations of the free /3-subunit with- Overall, dimer-hCG and its free /3-subunit were highly correlated in serum samples from nonseminoma patients (r = 0.82, P <0.001, n = 379) (Figure 3a) . Remarkably, in the 112 samples taken from patients with pure seminoma, the correlation between hCG and hCG-/3 was less significant (r = 0.32, P <0.01) (F'igure 3b).
Determination of hCG (+ hCG-/3)
The occurrence of isolated dimer-hCG and isolated free /3-subunit increases in some cases of testicular cancer makes the simultaneous determination of both hCG and hCG-/3 useful for diagnosis and follow-up of these patients. This can be done either by using two different assay procedures or, more conveniently in clinical practice, by using a single assay for dimer-hCG that is also sensitive for the free /3-subunit. The next part of our studies was undertaken to define the sensitivity and specificity of this Only samples with an increasein at least one of the two markersare included Of the 443 samples with no detectable hCG or free hCG-/3, results by the hCG (+hCG-/3) IRMA were negative in 403 cases (91.0%) and by the hCG (+hCG-/3) RIA in 370 cases (83.5%). These data implicate a loss of sensitivity and specificity if a single assay for hCG (+hCG-p) determination is performed rather than two independent assays for dimer-hCG and the free /3-subunit.
The difference between the two hCG (+hCG-/3) assays with respect to "falsely" negative results was mainly due to samples with isolated hCG-/3 increases that were preferentially detected by the hCG (+hCG-/3) IRMA as a result of its higher /3-subunit cross-reactivity.
In this assay 45 of 46 samples with hCG-/3 increases without detectable dimerhCG were found positive (97.8%), whereas the hCG (+hCG-/3) RIA detected only 22 of these samples (47.8%). As shown in Figure 4 , /3-subunit cross-reactivity of the hCG (+hCG-/3) RIA is not high enough to detect free /3-subunit concentrations between 0.2 and -1.0 mt. unitjL. In contrast, /3-subunit cross-reactivity of the hCG (+hCG-f3) IRMA is high enough to detect slightly increased free /3-subunit even in serum samples without detectable dimer-hCG.
Cross-Reactivity of Commercial hCG Assays with the Free /3-Subunit
To find out the most useful methods in clinical practice, we tested 11 widely used commercial hCG-kits for their cross-reactivities with the free /3-subunit of hCG. Crossreactivities were evaluated on a molar basis by the addition of free /3-subunit (0.2nmol/L) to the zerostandard,which contained human serum without hCG or hCG-/3. We found cross-reactivities for hCG-/3 of between <3% and 264%, which is generally not high enough to detect slightly increased values of the free /3-subunit in samples without detectable dimer-hCG ( Table 2) .
As shown in Figure 5 , the largely discordant crossreactivities of the different kits with the free/3-subunit led to highly discordant results for hCG determinations of samples containing increased values of free hCG-/3.
Discussion
In the present study we evaluated the incidence of dimer-hCG secretion and the secretion of the free hCG-/3-subunit in patients with seminomatous and nonseininomatous testicular cancer. The data obtained should serve as a basis for determining which assay method for hCGdetermination, i.e., assays with or without /3-subunit crossreactivity, is most reliable in diagnosis and follow-up of Table 2 testicular cancer patients. As a prerequisite for these studies, we developed highly sensitive and specific monoclonal IRMA5, all of which show negligible cross-reactivities with other glycoprotein hormones, e.g., lutropin, follitropin, or thyrotropmn. One assay was specific for the determination of dimer-hCG and had a negligible (<0.1%) cross-reactivity with the free /3-subunit. The other immunoassay specific for the measurement of the free (3-subunit showed low cross-reactivities with various hCG preparations that might be contaminated with the free /3-subunit. The purest preparation available (a gift from Dr. Amir, Boston, MA) cross-reacted by only 0.36%. The assays' cross-reactivities are in good accordance with or superior to the data from other recently published immunoassay procedures (2-5, 9, 10, 16) .
The use of these highly specific immunoassays in >900 consecutive serum samples from testicular cancer patients gave positive results for hCG or hCG-/3 in 53% of these samples. Because serum samples were taken partlyfrom selected populations of patients, the data are not representative for the overall incidence of increased hCG and hCG-/3 concentrations in testicular cancer. In nonseminoma samples, selective increases of dimerhCG without increased hCG-/3 were observed in a few cases; increased hCG-/3 without detectable dimer-hCG occurved only in a few samples taken during the patients' follow-up. In most of the serum samples, we found concordant increases of both hCG and hCG-/3. The parallel behavior of the two markers in nonseminoma patients is additionally reflected by their highly significant coefficient of correlation.
In this context, the question arises whether the presence of free /3-subunit in serum samples is the result of hCG dissociation rather than the result of hCG-/3 secretion by the tumor. However, a relevant dissociation ofdimer-hCG was recently excluded by long-term incubation experiments with pregnancy sera (17) . Moreover, in vitro studies have documented the simultaneous production and secretion of dimer-hCG and its free /3-subunit in cell cultures from normal and malignant trophoblastic tissues (18). More recently, Hay (16) has added further evidence to this concept by correlating the proffles of hCG and subunit secretion with the results of immunohistochemical studies of neoplastic tissue, suggesting a relationship between tumor histology and different patterns of hCG and hCGsubunit secretion. In germ-cell neoplasms such as nonseminomatous testicular tumors,hCG productionwas localized to isolated giant trophoblastic cells that secrete predominantly hCG, but also some hCG-/3, and thus have a relatively constant hCG-/3 to hCG ratio. These results would provide a good pathophysiological basis for our serological data in nonseminoma patients, showing in most cases a concordant secretion of hCG and hCG-/3.
In patients with pure seminoma, the overall incidence of hCG secretion, according to several authors, is between 7% and 40%, depending on the stage of disease (19) (20) (21) . We have recently reportedan incidenceof hCG (+hCG-/3) of 12% and, in addition, provided first evidence for an isolated secretion of the free /3-subunit of hCG in some patients with pure seminoma (14). In accord with this, the present population of seminoma patients, which is partly identical with the recently published study group (14), showed a frequency of isolated hCG-/3 increasesof about 30% of the samples with detectablehCG and hCG-/3 concentrations. About 20% of these samples showed an isolated increase of dimer-hCG, and in about 50% a concomitant rise of hCG and hCG-/3 could be observed. In seminoma samples,hCG and hCG-/3 concentrations were significantly lower than in patients with nonseminomatous testicular cancer. Before initiation of treatment, hCG values >2500 mt. unitsfL and /3-subunit values >40 mt. units/L had been observed only in samples from patients with nonseminomatous cancer. Moreover, in seminoma samples the correlation between hCG and hCG-/3 was less significant than in nonseminoma samples, suggesting an unrelated secretion of the two markers in at leastsome patientswith "marker-positive" pure seminoma. The correlation of these serological results with immunohistochemical data concerning the localization of hCG and subunit production in seminoma tissue is currently under investigation (22). The occurrence of isolated increases of the free /3-subunit of hCG in patients with pure seminoma makes hCG-/3 an additional marker in this disease and suggests that the determination of both hCG and hCG-/3 will be useful for diagnosis and follow-up. However, the clinical and prognostical implications of these findings are still unclear. Whether hCG-positive or hCG-/3-positive seminoma must be regarded as a clinically distinct tumor entity, with worse prognosis than hCG-negative semi.noma, is currently under discussion. A worse prognosis was suggested by several authors (19) (20) (21) , whereas recent data from our own group argue against this (14). To answer this question, results of a current German multicenter study, which includes a large number of patients, should be awaited.
Concentrations of dimer-hCG and free /3-subunit can be determined either by two independent assay procedures or by a single assay that is sensitive for both hCG and hCG-/3. Because the second approach seems preferable and more convenient in clinical practice, we evaluatedthe sensitivities and specificities of two hCG (+hCG-/3) assays, one a polyclonaldouble-antibody RIA and the other a monoclonal IRMA. Both assays showed rather high sensitivities and unitfL without detectable dimer-hCG could be detected only with the hCG (+hCG-/3) IRMA as a result of its higher molar cross-reactivity with the free (3-subunit (720% vs 234% in the RIA). These amounts ofhCG-/3, as seen in some samples from seminoma patients, gave negative results in the hCG (+hCG-/3) RIA with its lower hCG-/3 cross-reactivity. Therefore, for the diagnosis and follow-up of patients with pure seminoma, we recommend hCG assays with a high /3-subunit cross-reactivity in the range of that of our hCG (+hCG-/3) IRMA.
We found values between <3% and 264% after testing 11 widely used commercial hCG-kits fortheircross-reactivity with the free /3-subunit. As discussed above, the use of these kits would cause falsely negative results in some serum samples with slight increases of hCG-/3 in the absence of detectable dimer-hCG. Another important aspect of these data is that the measurement of a single hCG-/3-positive serum sample in hCG kitshaving different hCG-/3 cross-reactivities would give highly discordant results, even if all assays were standardized against the same hCG standard preparation. This must be kept in mind for hCG determinations performed in the follow-up of testicular cancer patients and makes mandatory the use of a single hCG kit in the follow-up of an individual patient.
In conclusion, the present study clearly establishes increased serum values of the free /3-subunit of hCG in the majority of patients with testicular cancer. In samples from nonseminoma patients, the concentrations of the two markers, hCG and hCG-/3, are generally well correlated. Consequently, the determination of hCG-/3 adds no further information in patients with nonseminomatous germ cell tumors. In contrast, in seminoma patients, the correlation between hCG and hCG-/3 is less significant, and increased concentrations of the free /3-subunit without detectable dimer-hCG could be observed in about 30% of the "marker-positive" samples, i.e., in about 5% of our seminoma patients. Thus the determination of both hCG and hCG-/3 gives the highest sensitivity in the diagnosis and follow-up of these patients. Because hCG-/3 can be quantified without the need of a further assay procedure if one uses assay methods that measure both hCG and hCG-/3, these assays are recommended as the most reliable and convenient methods for the diagnosis and followup of testicular cancer patients. For the detection of even slightly increased hCG-/3 concentrations, the hCG-f3 crossreactivities of these assays should be in the range of our hCG (+hCG-/3) IRMA (i.e., 720% on a molar basis). However, this value is not reached by the 11 widely used commercial hCG (+hCG-/3) kits we tested in this study and should be considered in the development of new assays systems.
